{"id":1819,"date":"2019-09-25T22:22:24","date_gmt":"2019-09-25T20:22:24","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1819"},"modified":"2024-03-07T16:28:21","modified_gmt":"2024-03-07T15:28:21","slug":"radiobiology-cancer-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/radiobiology-cancer-2\/","title":{"rendered":"Radiobiology & Cancer"},"content":{"rendered":"\n
The Radiobiology and Cancer group, led by Ferran Guedea, works on the translational aspect of integrating radiobiological findings into clinical patient outcome parameters and clinical studies<\/p>\n
Guix,I;Liu,Q;Pujana,MA;Ha,P;Piulats,J;Linares,I;Guedea,F et al, Validation of anti-correlated TGF\u00df signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy<\/strong>., Clin. Cancer Res., 2022;28(7):1372-1382, doi:10.1158\/1078-0432.CCR-21-2846<\/p>\n Garg,G;Finger,PT;Kivel\u00e4,TT;Simpson,ER;Gallie,BL;Saakyan,S;Amiryan,AG et al, Patients presenting with metastases: stage IV uveal melanoma, an international study<\/strong>., Br J Ophthalmol, 2022;106(4):510-517, doi:10.1136\/bjophthalmol-2020-317949<\/p>\n de Rooij,BH;van den Hurk,C;Smaardijk,V;Fernandez Ortega,P;Navarro Martin,A;Barberio,L;Guckenberger,M et al, Development of an updated, standardized, patient-centered outcome set for lung cancer<\/strong>., LUNG CANCER, 2022;1735-13, doi:10.1016\/j.lungcan.2022.08.021<\/p>\n Su\u00e1rez,JF;Zamora,V;Garin,O;Guti\u00e9rrez,C;Pont,\u00c0;Pardo,Y;Go\u00f1i,A et al, Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study<\/strong>., Sci Rep, 2022;12(1):12589-12589, doi:10.1038\/s41598-022-16395-w<\/p>\n Caminal,JM;Lorenzo,D;Gutierrez,C;Slocker,A;Piulats,JM;Cobos,E;Garcia Bru,P et al, Local Resection in Choroidal Melanoma: A Review<\/strong>, J. Clin. Med., 2022;11(23):doi:10.3390\/jcm11237156<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t MCI22002. RADIOTERAPIA DE PRECISI\u00d3N: FIRMA MOLECULAR PREDICTIVA PARA RADIOSENSIBILIDAD EN C\u00c1NCER DE MAMA<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 110013. 2022-2025. PI: Guedea Edo, Ferran.<\/p>\n 15ACL136. MEDIDA DEL IMPACTO DE LA RADIOTERAPIA CON INTENCI\u00d3N CURATIVA COMBINADA O NO CON TERAPIA HORMONAL SOBRE LA CALIDAD DE VIDA EN LA PR\u00c1CTICA CL\u00cdNICA EN EL C\u00c1NCER DE PR\u00d3STATA LOCALIZADO<\/strong>. ESTUDIO VEPIC-ORT. 2015-2023. PI: Boladeras Inglada, Ana M\u00aa.<\/p>\n 11ACL037. ENSAYO CL\u00cdNICO DE PRUEBA DE CONCEPTO, MULTIC\u00c9NTRICO, PROSPECTIVO, ALEATORIZADO, ABIERTO Y PARALELO, PARA VALORAR LA EFICACIA DE LA BRAQUITERAPIA CON O SIN TRATAMIENTO HORMONAL CON TRIPTORELINA 22,5 MG SEMESTRAL EN PACIENTES CON C\u00c1NCER DE.<\/strong> IPSEN. 2011-2023. PI: Guti\u00e9rrez Migu\u00e9lez, Cristina.<\/p>\n 11ACL217. ESTUDIO PARA EVALUAR EL IMPACTO DEL TRATAMIENTO DE BLOQUEO ANDROG\u00c9NICO EN LA INCIDENCIA DE ALTERACIONES METAB\u00d3LICAS EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA<\/strong>. ASTRAZENECA. 2011-2023. PI: Ferrer Gonz\u00e1lez, Ferran.<\/p>\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t We currently have three industry-funded projects under way:<\/p>\nImmune modulation through brachytherapy in blood and tumour microenvironment. Radiobiology & Cancer Summary The Radiobiology and Cancer group, led by Ferran Guedea, works on the translational aspect of integrating radiobiological findings into clinical patient outcome parameters and clinical studies 514 Publications Strategic lines Expand Study on: 1. How high doses of radiotherapy (SBRT, IORT and HDR) could trigger immune stimulation through modulation of cytokines […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-07 14:04:35","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1819"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=1819"}],"version-history":[{"count":7,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1819\/revisions"}],"predecessor-version":[{"id":23748,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1819\/revisions\/23748"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=1819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nDetection of systemic immune response to peripheral blood provided by high doses of radiation given to the lung in stereotactic conditions.
\nINTRABEAM: precision hypofractionated radiotherapy with immune-system response.
\nOver the past five years, we have obtained two competitive projects, Healthcare Research and Development Strategy grants:
\nLong-term effectiveness: 10-year follow-up of the “Spanish Multicentre Study of Localised Prostate Cancer” cohort (PI13 \/ 00412).
\nEfficacy of new treatments for low-risk localised prostate cancer: a randomised clinical trial (PI13 \/ 00412).\n\t\t\t\t\n\n\t\tGuedea Edo, Ferran\n\t<\/h4>\n
\n\t\t\n\t\tfguedea@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\n
\n\t\tGuedea Edo, Ferran\n\t<\/h4>\n
\n\t\t\n\t\tfguedea@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tMacia Garau, Miquel\n\t<\/h4>\n
\n\t\t\n\t\tmmacia@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tNavarro Martin, Arturo\n\t<\/h4>\n
\n\t\t\n\t\tanavarro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tFerrer Gonz\u00e1lez, Ferran\n\t<\/h4>\n
\n\t\t\n\t\tfferrer@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tGutierrez Miguelez, Cristina\n\t<\/h4>\n
\n\t\t\n\t\tcgutierrez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tBoladeras Inglada, Anna Mar\u00eda\n\t<\/h4>\n
\n\t\t\n\t\taboladeras@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tRibes Bernal, Juan Luis\n\t<\/h4>\n
\n\t\t\n\t\tjribesb@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tEraso Urien, Mar\u00eda Aranzazu\n\t<\/h4>\n
\n\t\t\n\t\tmeraso@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tLinares Galiana, Isabel\n\t<\/h4>\n
\n\t\t\n\t\tilinares@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tMartinez Perez, Evelyn\n\t<\/h4>\n
\n\t\t\n\t\temartinezp@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tManagement support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tBrachytherapy in early-stage breast cancer tumors is faster and with fewer side effects than conventional radiotherapy<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t07\/03\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL receives 1.2 million euros in grants to promote scientific research and its transfer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/01\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tNew chair to promote research in precision radiation oncology<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t15\/06\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tThe consul general of France in Barcelona visits IDIBELL<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t25\/10\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tQuantum technology and cancer. Research and application in its detection and treatment<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t01\/07\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL-ICO and VHIO public outreach to promote the importance of translational research in improving outcomes for patients with prostate cancer<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t21\/11\/2018\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"